Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1964 2
1965 3
1966 1
1967 7
1968 2
1969 13
1970 11
1971 6
1972 10
1973 2
1974 6
1975 8
1976 4
1977 5
1978 7
1979 5
1980 5
1981 5
1982 10
1983 13
1984 13
1985 12
1986 15
1987 19
1988 8
1989 25
1990 23
1991 18
1992 26
1993 38
1994 19
1995 26
1996 28
1997 38
1998 36
1999 39
2000 32
2001 46
2002 50
2003 37
2004 40
2005 61
2006 57
2007 84
2008 64
2009 85
2010 99
2011 112
2012 97
2013 112
2014 108
2015 140
2016 128
2017 131
2018 127
2019 128
2020 123
2021 168
2022 137
2023 124
2024 133
2025 106
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,722 results

Results by year

Filters applied: . Clear all
Page 1
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.
Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakamura H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Chida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H. Kumagai S, et al. Among authors: doi t. Cancer Cell. 2022 Feb 14;40(2):201-218.e9. doi: 10.1016/j.ccell.2022.01.001. Epub 2022 Jan 28. Cancer Cell. 2022. PMID: 35090594 Free article.
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590 Investigators. Sun JM, et al. Among authors: doi t. Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4. Lancet. 2021. PMID: 34454674 Clinical Trial.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Among authors: doi t. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Free PMC article. Clinical Trial.
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, Bariani GM, De Jesus Acosta A, Doi T, Longo F, Miller WH, Oh DY, Gottfried M, Xu L, Jin F, Norwood K, Marabelle A. Maio M, et al. Among authors: doi t. Ann Oncol. 2022 Sep;33(9):929-938. doi: 10.1016/j.annonc.2022.05.519. Epub 2022 Jun 6. Ann Oncol. 2022. PMID: 35680043 Free article. Clinical Trial.
Microbiota-driven antitumour immunity mediated by dendritic cell migration.
Lin NY, Fukuoka S, Koyama S, Motooka D, Tourlousse DM, Shigeno Y, Matsumoto Y, Yamano H, Murotomi K, Tamaki H, Irie T, Sugiyama E, Kumagai S, Itahashi K, Tanegashima T, Fujimaki K, Ito S, Shindo M, Tsuji T, Wake H, Watanabe K, Maeda Y, Enokida T, Tahara M, Yamashita R, Fujisawa T, Nomura M, Kawazoe A, Goto K, Doi T, Shitara K, Mano H, Sekiguchi Y, Nakamura S, Benno Y, Nishikawa H. Lin NY, et al. Among authors: doi t. Nature. 2025 Aug;644(8078):1058-1068. doi: 10.1038/s41586-025-09249-8. Epub 2025 Jul 14. Nature. 2025. PMID: 40659786 Free PMC article.
Japan-Multimodal Intervention Trial for the Prevention of Dementia: A randomized controlled trial.
Sakurai T, Sugimoto T, Akatsu H, Doi T, Fujiwara Y, Hirakawa A, Kinoshita F, Kuzuya M, Lee S, Matsumoto N, Matsuo K, Michikawa M, Nakamura A, Ogawa S, Otsuka R, Sato K, Shimada H, Suzuki H, Suzuki H, Takechi H, Takeda S, Uchida K, Umegaki H, Wakayama S, Arai H; J‐MINT study group. Sakurai T, et al. Among authors: doi t. Alzheimers Dement. 2024 Jun;20(6):3918-3930. doi: 10.1002/alz.13838. Epub 2024 Apr 22. Alzheimers Dement. 2024. PMID: 38646854 Free PMC article. Clinical Trial.
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration.
Rodon J, Prenen H, Sacher A, Villalona-Calero M, Penel N, El Helali A, Rottey S, Yamamoto N, Ghiringhelli F, Goebeler ME, Doi T, Postel-Vinay S, Lin CC, Liu C, Chuang CH, Keyvanjah K, Eggert T, O'Neil BH. Rodon J, et al. Among authors: doi t. Ann Oncol. 2024 Dec;35(12):1138-1147. doi: 10.1016/j.annonc.2024.08.2339. Epub 2024 Sep 16. Ann Oncol. 2024. PMID: 39293516 Clinical Trial.
2,722 results